Showing results (121-130 of 136) with videos related to
Sort By:
Pageof 14
Cancers|June 24, 2022
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 ProtocolMonica Messina, Alfonso Piciocchi, Tiziana Ottone, et al.Haematologica|November 1, 2019
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trialRiccardo Bruna, Fabio Benedetti, Carola Boccomini, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2024
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trialLuca Guerra, Stephane Chauvie, Federico Fallanca, et al.British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.Blood|September 6, 2013
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndromeEkaterina Chigrinova, Andrea Rinaldi, Ivo Kwee, et al.Lancet (London, England)|May 5, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.Lancet (London, England)|May 14, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.Blood Advances|June 25, 2026
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular LymphomaBarbara Botto, Carola Boccomini, Andrea Evangelista, et al.Hemasphere|June 8, 2026
Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trialNawar Maher, Riccardo Moia, Mohammad Almasri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialMarco Ladetto, Katja Gutmair, Rita Tavarozzi, et al.Pageof 14